MX2017004658A - Sulfatos de colesterol oxigenado para terapia contra trastornos provocados por al menos uno de actividad atenuada de leptina y un trastorno de almacenamiento lipidico. - Google Patents
Sulfatos de colesterol oxigenado para terapia contra trastornos provocados por al menos uno de actividad atenuada de leptina y un trastorno de almacenamiento lipidico.Info
- Publication number
- MX2017004658A MX2017004658A MX2017004658A MX2017004658A MX2017004658A MX 2017004658 A MX2017004658 A MX 2017004658A MX 2017004658 A MX2017004658 A MX 2017004658A MX 2017004658 A MX2017004658 A MX 2017004658A MX 2017004658 A MX2017004658 A MX 2017004658A
- Authority
- MX
- Mexico
- Prior art keywords
- therapy
- disorders caused
- lipid storage
- leptin activity
- storage disorder
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 6
- 102000016267 Leptin Human genes 0.000 title abstract 2
- 108010092277 Leptin Proteins 0.000 title abstract 2
- 230000002238 attenuated effect Effects 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title abstract 2
- 229940039781 leptin Drugs 0.000 title abstract 2
- 230000013190 lipid storage Effects 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 1
- 235000012000 cholesterol Nutrition 0.000 title 1
- -1 cholesterol sulfates Chemical class 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 abstract 1
- 230000006372 lipid accumulation Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Se proporcionan métodos y composiciones para la prevención y/o tratamiento de los sintomas asociados con los trastornos de acumulación de lípidos provocados por la actividad atenuada de leptina y por trastornos del almacenamiento lipídico. Los métodos implican administrar al menos un sulfato de colesterol oxigenado (OCS) a un sujeto con este trastorno. El trastorno puede ser adquirido o congénito (hereditario).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462062260P | 2014-10-10 | 2014-10-10 | |
| PCT/US2015/055262 WO2016058000A1 (en) | 2014-10-10 | 2015-10-13 | Oxygenated cholesterol sulfates for therapy of disorders caused by at least one of attenuated leptin activity and a lipid storage disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017004658A true MX2017004658A (es) | 2017-07-17 |
| MX376196B MX376196B (es) | 2025-03-07 |
Family
ID=54478210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004658A MX376196B (es) | 2014-10-10 | 2015-10-13 | Sulfatos de colesterol oxigenado para terapia contra trastornos provocados por al menos uno de actividad atenuada de leptina y un trastorno del almacenamiento lipidico. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20170252355A1 (es) |
| EP (1) | EP3204013A1 (es) |
| JP (2) | JP2017530174A (es) |
| KR (1) | KR20170066507A (es) |
| CN (1) | CN107106576A (es) |
| AU (3) | AU2015329716A1 (es) |
| BR (1) | BR112017007025A2 (es) |
| CA (1) | CA2962500A1 (es) |
| EA (1) | EA034524B1 (es) |
| IL (1) | IL251290A0 (es) |
| MX (1) | MX376196B (es) |
| WO (1) | WO2016058000A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| MX2021011641A (es) | 2013-12-24 | 2023-03-10 | Durect Corp | Usos de sulfatos de colesterol oxigenados (soc). |
| CA3021900A1 (en) * | 2016-04-29 | 2017-11-02 | Orphazyme A/S | Arimoclomol for treating glucocerebrosidase associated disorders |
| HUE059768T2 (hu) * | 2016-08-02 | 2022-12-28 | Univ Virginia Commonwealth | 5-kolesztén-3,25-diol, 3-szulfátot (25HC3S) vagy annak gyógyszerészetileg elfogadható sóját és legalább egy ciklikus oligoszacharidot tartalmazó készítmények |
| KR102462275B1 (ko) * | 2016-08-02 | 2022-11-01 | 듀렉트 코퍼레이션 | 산소화 콜레스테롤 술페이트, 및 폴리알킬렌 글리콜, 카르복시메틸 셀룰로오스 및 폴리옥실글리세리드 중 적어도 하나를 포함하는 조성물 |
| US20200276211A1 (en) * | 2017-11-28 | 2020-09-03 | Viewpoint Therapeutics, Inc. | Compounds for treating near vision disorders |
| EP4171504A4 (en) * | 2020-06-26 | 2024-07-10 | Durect Corporation | USE OF OXYGENATED CHOLESTEROL SULFATES FOR THE TREATMENT OF AUTOIMMUNE CONDITIONS |
| EP4359420A4 (en) * | 2021-06-25 | 2025-07-16 | Durect Corp | 25-HYDROXY-CHOLEST-5-EN-3-SULFATE CHOLINE, PROCESSES FOR THEIR PREPARATION, AND THEIR USES |
| JP2026501266A (ja) * | 2022-12-23 | 2026-01-14 | デュレクト コーポレーション | ２５－ヒドロキシ－コレスタ－５－エン－３－スルファートの結晶性塩を含む塩、及びその調製方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| US8399441B2 (en) * | 2004-10-25 | 2013-03-19 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
| US8044243B2 (en) | 2006-02-13 | 2011-10-25 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US8003795B2 (en) | 2007-06-22 | 2011-08-23 | Cvi Pharmaceuticals Limited | Compounds and compositions for reducing lipid levels |
| US9034859B2 (en) * | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
| CN106083976B (zh) | 2012-04-12 | 2018-02-09 | 弗吉尼亚联邦大学 | 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5‑胆甾烯‑3β,25‑二醇二硫酸酯(25HCDS) |
-
2015
- 2015-10-13 CN CN201580054842.8A patent/CN107106576A/zh active Pending
- 2015-10-13 AU AU2015329716A patent/AU2015329716A1/en not_active Abandoned
- 2015-10-13 JP JP2017518508A patent/JP2017530174A/ja active Pending
- 2015-10-13 EP EP15791393.0A patent/EP3204013A1/en not_active Withdrawn
- 2015-10-13 KR KR1020177011640A patent/KR20170066507A/ko not_active Ceased
- 2015-10-13 MX MX2017004658A patent/MX376196B/es active IP Right Grant
- 2015-10-13 US US15/517,395 patent/US20170252355A1/en not_active Abandoned
- 2015-10-13 WO PCT/US2015/055262 patent/WO2016058000A1/en not_active Ceased
- 2015-10-13 BR BR112017007025A patent/BR112017007025A2/pt not_active Application Discontinuation
- 2015-10-13 CA CA2962500A patent/CA2962500A1/en not_active Abandoned
- 2015-10-13 EA EA201790791A patent/EA034524B1/ru not_active IP Right Cessation
-
2017
- 2017-03-20 IL IL251290A patent/IL251290A0/en unknown
-
2018
- 2018-08-22 US US16/108,286 patent/US20190083509A1/en not_active Abandoned
-
2019
- 2019-10-04 US US16/593,460 patent/US20200138831A1/en not_active Abandoned
-
2020
- 2020-10-09 JP JP2020170860A patent/JP2021008506A/ja active Pending
- 2020-11-02 US US17/087,364 patent/US20210161913A1/en not_active Abandoned
-
2021
- 2021-01-29 AU AU2021200574A patent/AU2021200574A1/en not_active Abandoned
- 2021-04-15 AU AU2021202288A patent/AU2021202288A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021008506A (ja) | 2021-01-28 |
| US20200138831A1 (en) | 2020-05-07 |
| AU2021200574A1 (en) | 2021-03-04 |
| US20170252355A1 (en) | 2017-09-07 |
| CA2962500A1 (en) | 2016-04-14 |
| IL251290A0 (en) | 2017-05-29 |
| US20210161913A1 (en) | 2021-06-03 |
| MX376196B (es) | 2025-03-07 |
| EA201790791A1 (ru) | 2017-08-31 |
| EP3204013A1 (en) | 2017-08-16 |
| CN107106576A (zh) | 2017-08-29 |
| AU2015329716A1 (en) | 2017-04-13 |
| EA034524B1 (ru) | 2020-02-17 |
| BR112017007025A2 (pt) | 2017-12-12 |
| WO2016058000A1 (en) | 2016-04-14 |
| KR20170066507A (ko) | 2017-06-14 |
| JP2017530174A (ja) | 2017-10-12 |
| AU2021202288A1 (en) | 2021-05-13 |
| US20190083509A1 (en) | 2019-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017004658A (es) | Sulfatos de colesterol oxigenado para terapia contra trastornos provocados por al menos uno de actividad atenuada de leptina y un trastorno de almacenamiento lipidico. | |
| ZA201806633B (en) | Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors | |
| EP3662903A3 (en) | Combination therapies | |
| WO2014205389A8 (en) | Nuclear transport modulators and uses thereof | |
| MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
| WO2013061161A3 (en) | New combination therapies for treating neurological disorders | |
| GT201300209A (es) | Compuestos y composiciones como inhibidores de la trk | |
| PH12015500879A1 (en) | Compositions and methods for treating proteinopathies | |
| IN2015DN00438A (es) | ||
| GB2542155B (en) | Use of cannabidiol in the treatment of mental disorders | |
| IL225239A0 (en) | Compounds for the treatment of acne and related diseases | |
| WO2016077639A3 (en) | Nanovesicular therapies | |
| AP2014007804A0 (en) | Compositions and methods for the treatment of hepatic diseases and disorders. | |
| MX2015003048A (es) | Tratamiento del trastorno de estres post-traumatico con mycobacterium aislado. | |
| PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
| WO2014080286A3 (en) | Methods and compositions for treating multiple sclerosis and related disorders | |
| PH12017500615A1 (en) | Ophthalmic composition comprising cyclosporine and trehalose | |
| EP3182990A4 (en) | Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the ifp35 family of proteins | |
| EP3125944A4 (en) | Methods and compositions for administering an active agent to the pleura of a patient | |
| IL238415A0 (en) | Compositions and methods for treating or preventing diseases or disorders associated with eif4e dysregulation | |
| HK1213175A1 (zh) | Tspo介导的疾病和/或病症的治疗和/或预防 | |
| MX356317B (es) | Tratamiento de síntomas asociados a gastroparesia femenina. | |
| HK1246653A1 (zh) | 奥那司酮延长释放组合物和方法 | |
| NZ724799A (en) | Compositions and methods for the treatment or prevention of neurodegenerative disorders | |
| WO2013049272A3 (en) | Composition and method for treatment of symptoms associated with various skin conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |